The key to a new drug’s commercial success is making it efficacious, cost-effective, easy to manufacture, and patient-friendly. For these reasons, the oral solid dosage form remains the largest segment of the global pharmaceutical market. However, the increasing complexity of today’s APIs and the growing need for more patient-centric delivery formats, such as smaller tablets or reduced dosing frequency, create challenges for drug manufacturers. Here, Lubrizol explains how innovative excipients can unlock new options for more efficacious and patient-friendly therapeutics.
Please check the highlighted fields and try again.